EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Probiotic-drug co-delivery system enhances sulfasalazine activation for inflammatory bowel disease therapy

Luo Zhao, Xinxin Liu, Fangfang Wang, Mengya Niu, Zilin Ma, Ziqing Wang, Yange Du, Shuang Gong, Yuanyuan Li, Qingling Song, Yun Zhang, Lei Wang

Materials Today Bio · 2026-02 · 36 · 102669

DOI: 10.1016/j.mtbio.2025.102669 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Materials Today Bio, 2026-02. Verfasst von Luo Zhao und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Zhengzhou University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory bowel disease (IBD), affecting millions of patients worldwide, is associated with mucosal inflammation and gut microbiota dysbiosis. As a prodrug of 5-aminosalicylic acid (5-ASA), sulfasalazine (SSZ) is a first-line medication for IBD. However, SSZ exhibits limited clinical efficacy due to its nonspecific systemic distribution and the inefficient cleavage of the azo bond, which results from inadequate azo reductase (AR) activity. Intriguingly, we found that Clostridium butyricum (CB) possess AR activity and can metabolize SSZ into 5-ASA. Here, we develop a pH and enzyme dual-responsive drug delivery system CBs/SSZ/CS/EudS-100 by encapsulating the SSZ-loaded Clostridium butyricum spore (CBs) with chitosan (CS) and Eudragit S100 (EudS-100). After oral administration, it is identified that the CS and EudS-100 coating enables the colonic release of SSZ. On the one hand, CBs germinates into CB, which facilitates the conversion of SSZ to 5-ASA, relieving inflammation and repairing intestinal barrier. On the other hand, CB modulates the disordered gut microbiota. This provides a new strategy for integrating probiotic therapy with pharmacological treatment in the management of IBD.

Schlagwörter

Stichwörter der Autor:innen

Azo reductaseClostridium butyricumGut microbiotaInflammatory bowel diseaseSulfasalazine

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
  • Henan Key Laboratory of Nanomedicine for Targeting Diagnosis and Treatment, Zhengzhou, 450001, China.
  • Tumor Immunity and Biomaterials Advanced Medical Center, Zhengzhou University, Luoyang, 471009, China.
  • Tianjian Laboratory of Advanced Biomedical Sciences, Zhengzhou University, 450001, China.

Förderung

  • Zhengzhou University
  • National Natural Science Foundation of China

Zitieren

APA

Zhao, L., Liu, X., Wang, F., Niu, M., Ma, Z., Wang, Z., Du, Y., Gong, S., Li, Y., Song, Q., Zhang, Y., & Wang, L. (2026). Probiotic-drug co-delivery system enhances sulfasalazine activation for inflammatory bowel disease therapy. Materials Today Bio, 36, 102669. https://doi.org/10.1016/j.mtbio.2025.102669

Vancouver

Zhao L, Liu X, Wang F, Niu M, Ma Z, Wang Z, et al. Probiotic-drug co-delivery system enhances sulfasalazine activation for inflammatory bowel disease therapy. Materials Today Bio. 2026;36:102669. doi:10.1016/j.mtbio.2025.102669

BibTeX
@article{Zhao2026,
  author = {Zhao, Luo and Liu, Xinxin and Wang, Fangfang and Niu, Mengya and Ma, Zilin and Wang, Ziqing and Du, Yange and Gong, Shuang and Li, Yuanyuan and Song, Qingling and Zhang, Yun and Wang, Lei},
  title = {Probiotic-drug co-delivery system enhances sulfasalazine activation for inflammatory bowel disease therapy},
  journal = {Materials Today Bio},
  year = {2026},
  volume = {36},
  pages = {102669},
  doi = {10.1016/j.mtbio.2025.102669}
}
Kostenlos starten →